Tofflon Science and Technology Group News

Dongfulong (300171): Formulation Division Highlights Customer Expansion and Strengthening

浙商證券Dec 28, 2023 00:00

Research Report Nuggets: Huaxin Securities: Maintaining Tofulong's “Buy” Rating, Optimistic About Subsequent Product Release

Gelonghui FinanceDec 8, 2023 17:28

Dongfulong (300171): Steady growth in revenue, promising expansion in overseas markets

華鑫證券Dec 8, 2023 16:02

Dongfulong (300171): Oriental Dragons in the upstream pharmaceutical industry have always grasped the boom track

太平洋證券Dec 1, 2023 00:00

Dongfulong (300171): Under the influence of macro factors, the profit side is under pressure, and the fund-raising project is progressing smoothly

德邦證券Nov 14, 2023 19:06

Dongfulong (300171): Actively developing customers and looking forward to order resumption

中泰證券Oct 29, 2023 00:00

Dongfulong (300171): Revenue side growth is steady, pharmaceutical division and food division have impressive growth rates

國信證券Oct 7, 2023 00:00

Dongfulong (300171): Performance is growing steadily, and there is broad scope for domestic replacement of pharmaceutical equipment

華鑫證券Sep 28, 2023 00:00

Dongfulong (300171) 2023 Interim Report Review: Injections Drive Steady Performance Growth and Continued Market Share Expansion

中信證券Sep 22, 2023 18:12

Tofulon (300171): Steady revenue growth in the first half of 2023

西南證券Sep 3, 2023 00:00

Dongfulong (300171): Revenue side growth, steady gross margin fluctuations affect profit performance

國盛證券Aug 29, 2023 08:52

Dongfulong (300171) 2023H1 review: The injectables business drove rapid growth in performance in the first half of the year

中泰證券Aug 29, 2023 00:00

Dongfulong (300171): Revenue continues to grow steadily

國信證券May 19, 2023 00:00

Dongfulong (300171): Revenue for the single third quarter increased by 29.6% year on year and continued to promote internationalization & diversified layout

國信證券Nov 2, 2022 00:00

Dongfulong (300171): The pace of Q3 order delivery is improving, starting a new round of capacity expansion

中泰證券Oct 28, 2022 00:00

Dongfulong (300171): Revenue side growth is in line with expectations, short-term gross margin falls, putting pressure on profit side

國盛證券Oct 27, 2022 00:00

Dongfulong (300171): Pharmaceutical equipment leader creates second growth curve for consumables, CGT, etc.

中泰證券Oct 20, 2022 00:00

Dongfulong (300171) In-depth Report: Jiaolong's full-industry integration strategy breaks the cycle by going overseas

民生證券Oct 16, 2022 00:00

Dongfulong (300171): The epidemic disrupts growth, slows down production capacity optimization, unleashes potential

東北證券Sep 3, 2022 00:00

Dongfulong (300171): Expectations that overseas business will continue to develop throughout the year without changing the impact of the epidemic

招商證券Aug 31, 2022 00:00